Information Provided By:
Fly News Breaks for November 25, 2015
IMGN
Nov 25, 2015 | 06:26 EDT
Jefferies analyst Biren Amin upgraded ImmunoGen to Buy after assuming coverage of the name. Mirvetuximab has shown "robust activity" in patients with ovarian cancer that are highly expressing the folate receptor, and data from an additional 40 patients in Q2 of 2016 could be the next catalyst for the stock, Amin tells investors in a research note. He doubled his price target for ImmunoGen shares to $16 from $8.
News For IMGN From the Last 2 Days
There are no results for your query IMGN